3Holmes E,Antti H. Chemometric contributions to the evolution of metabonomics:Mathematical solutions to characterizing and interpreting complex biological NMR spectra[J].Analyst,2002,(12):1549.
2Reddy KS. The preventive polypill-much promise, insufficient evidence[J]. N Engl J Med, 2007, 356 (3): 212.
3Yusuf S. Two decades of progress in preventing vasculardisease[J]. Lancet, 2002, 360(9326):2-3.
4Wald N J, Law MR. A strategy to reduce cardiovascular disease by more than 80% [ J ]. BMJ, 2003,326 (7404) :1419.
5Indian Polycap Study (TIPS), Yusuf S, Pais P, et al. Effects of a polypill (Polycap) on risk factors in middle-aged individuals without cardiovascular disease (TIPS) : a phase Ⅱ , double-blind, randomised trial [ J ]. Lancet, 2009,373 ( 9672 ): 1341 - 1351.
7Sleight P, Pouleur H, Zannad F. Benefits, challenges, and registerability of the polypill [ J ]. Eur Heart J, 2006, 27(14) :1651-1656.
8Rastegarpanah M, al. A new horizon cular disease, can polypill" [ J ] ? Arch Malekzadeh F, Thomas GN, et n primary prevention of cardiovaswe prevent heart attack by " heart Iran Med, 2008,11 (3):306-313.
9Stirban AO, Tschoepe D. Should we be more aggressive in the therapy against cardiovascular risk factors[ J ] ? Diabetes Care, 2008, 31 ( Suppl 2 ) : S226- S228.
10Wang L, Zhou GB, Liu P, et al. Dissection of mechanisms of Chinese medicinal formula Realgar-lndigo naturalis as an effective treatment for promyelocytic leukemia[J]. Proc Natl Acad Sci USA, 2008,105 ( 12 ) :4826- 4831.
